

# Mark G Lebowhl

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4648314/mark-g-lebwohl-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

373  
papers

24,695  
citations

81  
h-index

151  
g-index

392  
ext. papers

28,757  
ext. citations

5.5  
avg, IF

7.06  
L-index

#	Paper	IF	Citations
373	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.. <i>Acta Dermato-Venereologica</i> , <b>2022</b> ,	2.2	4
372	Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicenter, retrospective cohort study.. <i>British Journal of Dermatology</i> , <b>2022</b> ,	4	0
371	TNF-Alpha Class of Biologic Agents in Psoriatic Disease. <i>Updates in Clinical Dermatology</i> , <b>2022</b> , 25-32	0.2	
370	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.. <i>Dermatology and Therapy</i> , <b>2022</b> , 12, 727	4	3
369	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17.. <i>Dermatology and Therapy</i> , <b>2022</b> , 12, 787	4	0
368	Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting.. <i>Dermatology and Therapy</i> , <b>2022</b> , 1	4	
367	Comment on "Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis". <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, e377	4.5	1
366	Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 360-368	4.5	10
365	Risk of skin disorders in patients with celiac disease: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 1456-1464	4.5	5
364	The Psoriasis Decision Tree. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2021</b> , 14, 14-22	1.2	
363	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	4
362	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , <b>2021</b> , 1	4	1
361	COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> ,	5.4	2
360	Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. <i>BMJ Open</i> , <b>2021</b> , 11, e043666	3	17
359	Durable remissions of guttate psoriasis following short courses of IL-17 inhibitors. <i>International Journal of Dermatology</i> , <b>2021</b> , 60, 1161-1162	1.7	0
358	Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-Severe psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-26	2.8	1
357	The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 935-944	4	10

356	POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 787-788	2.4	
355	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1254-1268	4.5	42
354	Biosimilars in Dermatology. <i>JAMA Dermatology</i> , <b>2021</b> , 157, 641-642	5.1	0
353	Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	5
352	Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1157-1174	4.4	1
351	Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-7	2.8	
350	The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1079-1083	4	0
349	Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 135-142	4.6	15
348	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 640-651	4	9
347	Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. <i>Dermatology</i> , <b>2021</b> , 237, 46-55	4.4	3
346	Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 432-470	4.5	46
345	Interleukin 12/23 Inhibitors <b>2021</b> , 302-311.e2		
344	Interleukin 17 Inhibitors <b>2021</b> , 312-320.e2		
343	Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 398-407	4.5	3
342	Two-Year US Pharmacovigilance Report on Brodalumab. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 173-180	4	6
341	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1269-1277	4.5	18
340	Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 85, 1657-1660	4.5	0
339	Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 221-233	4	6

338	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 487-498	4.0	51
337	Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35 Suppl 1, 35-41	4.6	4
336	Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 1152-1160	4.6	5
335	Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence From a Survey of Corrona Registry Dermatologists. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 529-541		7
334	Newer Therapies in Psoriasis. <i>Medical Clinics of North America</i> , <b>2021</b> , 105, 627-641	7	2
333	Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 840-842	4	0
332	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 2409-2414 <sup>1</sup>	4.6	1
331	Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1657-1665	4	0
330	Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ Years with Mild-to-Moderate Atopic Dermatitis. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1667-1678	4	0
329	The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-3	2.8	1
328	Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, 2398-2408	4.6	1
327	Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	8
326	Three-year U.S. pharmacovigilance report of brodalumab. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e15105	2.2	5
325	Psoriasis medications: The future. <i>Dermatological Reviews</i> , <b>2021</b> , 2, 296	0.2	
324	Phase 2a randomized clinical trial of dupilumab (anti-IL-4R $\alpha$ ) for alopecia areata patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	9.3	10
323	Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.. <i>Dermatology and Therapy</i> , <b>2021</b> , 12, 407	4	2
322	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 67-75	4	4
321	No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1436-1439	4.5	4

320	Malignancy Rates in Brodalumab Clinical Studies for Psoriasis. <i>American Journal of Clinical Dermatology</i> , <b>2020</b> , 21, 421-430	7.1	6
319	Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. <i>Lancet, The</i> , <b>2020</b> , 396, 110-120	4.0	59
318	Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 96-103	4.5	18
317	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1445-1486	4.5	79
316	Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 1744-1749	4.6	9
315	Apremilast and systemic retinoid combination treatment for moderate to severe palmoplantar psoriasis. <i>Cutis</i> , <b>2020</b> , 106, E15-E17	0.4	1
314	The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2020</b> , 13, 44-48	1.2	9
313	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 161-201	4.5	63
312	Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 63-70	4.5	17
311	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , <b>2020</b> , 10, 133-150	4	29
310	PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis. <i>Advances in Therapy</i> , <b>2020</b> , 37, 4730-4753	4.1	2
309	Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-9	2.8	4
308	Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1314-1320	4.5	23
307	Comment on "PGABSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis". <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, e289-e290	4.5	1
306	A Preliminary F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 3500-3506	5.4	2
305	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1704-1716	4.5	31
304	US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 31, 333-341	2.8	14
303	Immunogenicity and skin clearance recapture in clinical studies of brodalumab. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 344-351	4.5	13

302	Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 352-359	4.5	35
301	Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 519-522	4.5	9
300	Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 360-365	4.5	18
299	An update on generalized pustular psoriasis. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 907-919	5.1	50
298	Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. <i>American Journal of Clinical Dermatology</i> , <b>2019</b> , 20, 863-871	7.1	19
297	Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 886-892	4.6	19
296	Update on Risankizumab for Psoriasis. <i>Current Dermatology Reports</i> , <b>2019</b> , 8, 1-5	1.5	
295	Itch: an under-recognized problem in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 1465-1476	4.6	22
294	Magnesium supplementation in the treatment of pseudoxanthoma elasticum: A randomized trial. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 263-265	4.5	9
293	Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 2082-2086	4.6	4
292	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2019</b> , 4, 133-142	1.1	2
291	Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. <i>BMJ Open</i> , <b>2019</b> , 9, e027535	3	17
290	What's New in Psoriasis. <i>Dermatologic Clinics</i> , <b>2019</b> , 37, 129-136	4.2	12
289	A new era in the treatment of atopic dermatitis. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 658	4	
288	Reply to: "Comment on 'Magnesium supplementation in the treatment of pseudoxanthoma elasticum: Is magnesium oxide the best choice?'". <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, e137	4.5	0
287	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 775-804	4.5	47
286	Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 857-859	4.5	27
285	Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. <i>American Journal of Clinical Dermatology</i> , <b>2019</b> , 20, 711-723	7.1	11

284	Interleukin-23 blockade: another breakthrough in the treatment of psoriasis. <i>Lancet, The</i> , <b>2019</b> , 394, 544-546	4.0	3
283	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1029-1072	4.5	296
282	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1073-1113	4.5	145
281	Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 142-154	11.5	80
280	Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 43-53	4.5	149
279	Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 27-40	4.5	177
278	A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. <i>Archives of Dermatological Research</i> , <b>2019</b> , 311, 29-36	3.3	23
277	Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 282-285	4.5	14
276	Biologics and Psoriasis: The Beat Goes On. <i>Dermatologic Clinics</i> , <b>2019</b> , 37, 29-36	4.2	34
275	Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 2095-2107	11.5	24
274	Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 709-717	4.6	13
273	Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2019</b> , 33, 546-552	4.6	22
272	Review of safety and efficacy of approved systemic psoriasis therapies. <i>International Journal of Dermatology</i> , <b>2019</b> , 58, 649-658	1.7	47
271	Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>Journal of Dermatological Treatment</i> , <b>2019</b> , 30, 534-539 <sup>2.8</sup>	3.8	13
270	Adult-onset asymmetrical lipomatosis. <i>Cutis</i> , <b>2019</b> , 103, E4-E5	0.4	1
269	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 294-301.e6	4.5	16
268	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 266-276.e5	4.5	86
267	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 872-881.e6	4.5	172

266	Reply to: "Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials". <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, e75	4.5	1
265	Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. <i>American Journal of Clinical Dermatology</i> , <b>2018</b> , 19, 363-375	7.1	51
264	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 383-394	4.5	41
263	Miscellaneous Uses of Biologic and Systemic Agents in Other Dermatologic Conditions <b>2018</b> , 295-308		
262	Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 287-293	4.5	31
261	Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. <i>Experimental Dermatology</i> , <b>2018</b> , 27, 409-417	4	92
260	Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 323-332	4.5	47
259	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 741-748	4.5	18
258	Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 81-89.e5	4.5	95
257	Psoriasis. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, ITC49-ITC64	8	31
256	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , <b>2018</b> , 392, 650-661	4.0	283
255	Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, e57-e59	4.5	6
254	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. <i>JAMA Dermatology</i> , <b>2018</b> , 154, 934-950	5.1	70
253	TNF inhibitors for psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2018</b> , 37, 134-142	1.4	18
252	Psoriasis: Overview and Diagnosis. <i>Updates in Clinical Dermatology</i> , <b>2018</b> , 1-16	0.2	7
251	A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 733-740.e11	4.5	55
250	Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>American Journal of Clinical Dermatology</i> , <b>2018</b> , 19, 879-886	7.1	12
249	Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). <i>Dermatology and Therapy</i> , <b>2018</b> , 8, 571-579	4	38



248	Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. <i>Journal of Drugs in Dermatology</i> , <b>2018</b> , 17, 221-228	2.2	23
247	Melkersson-Rosenthal syndrome successfully treated with adalimumab. <i>Cutis</i> , <b>2018</b> , 101, 122-124	0.4	7
246	Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy. <i>Journal of Drugs in Dermatology</i> , <b>2018</b> , 17, 1280-1287	2.2	5
245	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , <b>2017</b> , 18, 405-411	7.1	16
244	Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. <i>Journal of Immunology</i> , <b>2017</b> , 198, 3809-3814	5.3	45
243	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 290-298	4.5	90
242	Pediatric Psoriasis Comorbidity Screening Guidelines. <i>JAMA Dermatology</i> , <b>2017</b> , 153, 698-704	5.1	54
241	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1867-1875	4.6	9
240	Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 849-862.e6	3.5	23
239	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , <b>2017</b> , 177, 587-590	4	6
238	Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 115-121	4	12
237	Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 1519-1531	5.4	82
236	Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. <i>F1000Research</i> , <b>2017</b> , 6, 1712	3.6	15
235	Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2017</b> , 2, 73-80	1.1	1
234	Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 845-854.e5	4.5	93
233	Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 372-374	4.5	32
232	Does Treatment of Psoriasis Reduce Cardiovascular Comorbidities?. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 1612-1613	4.3	10
231	Herpes zoster in psoriasis patients treated with tofacitinib. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 302-309	4.5	45

230	The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 667-674	4.5	62
229	Update on Ustekinumab for Psoriasis. <i>Current Dermatology Reports</i> , <b>2017</b> , 6, 29-34	1.5	
228	Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>Journal of Dermatological Treatment</i> , <b>2017</b> , 28, 282-287	2.8	35
227	Patient-reported impact of chronic urticaria compared with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , <b>2017</b> , 28, 229-236	2.8	16
226	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 432-440.e175	4.5	88
225	Burden of Psoriasis as Reported in a Cross-Sectional Study: Association of Psoriasis Severity with Health-Related Quality of Life, Depression, and Work Productivity. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2017</b> , 2, 106-112	1.1	2
224	Patient Satisfaction Scores and Standard of Care Compliance in Patients on Biologic Therapy for Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2017</b> , 2, 102-105	1.1	
223	Secukinumab and Apremilast Combination Therapy for Recalcitrant Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2017</b> , 2, 59-61	1.1	3
222	Topical Immune Response Modifiers: Adjuvants <b>2017</b> , 775-790		
221	A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. <i>Journal of Drugs in Dermatology</i> , <b>2017</b> , 16, 197-204	2.2	17
220	Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. <i>Skinmed</i> , <b>2017</b> , 15, 119-124	0.2	19
219	Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. <i>Journal of Drugs in Dermatology</i> , <b>2017</b> , 16, 801-808	2.2	30
218	The state and consequences of dermatology drug prices in the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 603-605	4.5	15
217	Psoriasis Therapy: Breakthroughs in Pharmacogenomics or in Pharmacology?. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 2339-2340	4.3	3
216	Psoriasis. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16082	51.1	327
215	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 494-503.e6	4.5	286
214	Review of Available and Investigational Biologics and Non-Biologic Small Molecules for the Treatment of Plaque Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2016</b> , 2, 11-21	1.1	3
213	Adherence to topical therapies in actinic keratosis: A literature review. <i>Journal of Dermatological Treatment</i> , <b>2016</b> , 27, 538-545	2.8	8

212	Translating psoriasis guidelines into practice: Important gaps revealed. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 544-51	4.5	3
211	Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 301-304	11.5	48
210	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 851-61.e4	4.5	59
209	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>American Journal of Clinical Dermatology</i> , <b>2016</b> , 17, 87-97	7.1	121
208	Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 127-33	4.5	25
207	Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2016</b> , 8, 34-41	1.2	17
206	Efficacy and safety of ustekinumab in adolescents. <i>Pediatric Health, Medicine and Therapeutics</i> , <b>2016</b> , 7, 109-120	2.5	13
205	Relationship between severity of the local skin reactions and the rate of local skin reaction resolution in patients treated with ingenol mebutate gel. <i>Clinical, Cosmetic and Investigational Dermatology</i> , <b>2016</b> , 9, 211-6	2.9	4
204	Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2016</b> , 1, 167-174	1.1	0
203	Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. <i>International Journal of Dermatology</i> , <b>2016</b> , 55, 401-7	1.7	27
202	Use of 308 nm excimer laser for the treatment of chronic hand and foot eczema. <i>International Journal of Dermatology</i> , <b>2016</b> , 55, e447-53	1.7	11
201	Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. <i>International Journal of Dermatology</i> , <b>2016</b> , 55, e147-55	1.7	13
200	Ustekinumab as therapy for psoriasis in a 2-year-old girl. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, e109-e110	4.6	5
199	THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 253.1-253	2.4	
198	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 77-82.e7	4.5	65
197	Actinic Keratosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1394-5	27.4	3
196	Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. <i>Journal of Drugs in Dermatology</i> , <b>2016</b> , 15, 390-6	2.2	50
195	Afamelanotide for Erythropoietic Protoporphyrria. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 48-59	59.2	145

194	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <i>Lancet, The</i> , <b>2015</b> , 386, 541-51	4 <sup>0</sup>	576
193	Evaluating the economic burden of psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 961-7.e5	4.5	79
192	Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors". <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 744	4.5	2
191	IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 1946-1953	4.3	5 <sup>0</sup>
190	Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>JAMA Dermatology</i> , <b>2015</b> , 151, 961-9	5.1	247
189	Indications and limitations of afamelanotide for treating vitiligo-reply. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 350	5.1	3
188	Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 42-50	5.1	97
187	Phototherapy in dermatology: A call for action. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 1078-80	4.5	39
186	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1318-28	59.2	53 <sup>0</sup>
185	SAT0559 Malignancies in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Study: Current Status of Observations. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 862.2-862	2.4	
184	Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 1277-87	11.5	132
183	Annual screening for tuberculosis in patients on TNF-alfa antagonists. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, e123	4.5	
182	Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. <i>British Journal of Dermatology</i> , <b>2015</b> , 172, 1371-83	4	147
181	FRI0123 Clinical Outcomes Associated with Switching or Discontinuation of Anti-TNF Inhibitors for Non-Medical Reasons. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 465.1-465	2.4	3
180	SAT0560 Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Current Status of Observations. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 862.3-863	2.4	
179	Do we need more psoriasis therapies?. <i>Lancet, The</i> , <b>2015</b> , 386, 512-4	4 <sup>0</sup>	3
178	Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stage Basal Cell Carcinomas while Reducing the Use of Diagnostic Biopsy. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2015</b> , 8, 14-20	1.2	33
177	Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys. <i>Cutis</i> , <b>2015</b> , 95, 173-8	0.4	17

176	Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 525-32	4.5	24
175	From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 168-77	4.5	107
174	Research gaps in psoriasis: opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 146-67	4.5	85
173	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 1176-82	4.5	87
172	Reply to 'complementary data for long-term infliximab use in psoriasis'. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 591-2	4.5	1
171	An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 954-959.e1	4.5	9
170	Secukinumab in plaque psoriasis--results of two phase 3 trials. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 326-38	59.2	1319
169	Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 871-81.e1-30	4.5	332
168	A Reduction in Dosage of Acitretin to 17.5 mg/day Maintains Efficacy While Improving Tolerability. <i>Psoriasis Forum</i> , <b>2014</b> , 20a, 36-48		
167	Immunobiologics: Intermittent versus Continuous Use in the Treatment of Moderate to Severe Psoriasis. <i>Psoriasis Forum</i> , <b>2014</b> , 20a, 49-54		
166	Patient Perspectives on Psoriasis Management: U.S. Results of the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Psoriasis Forum</i> , <b>2014</b> , 20a, 124-131		2
165	Treatment of Refractory Psoriasis with Ustekinumab in an HIV-Positive Patient: A Case Presentation and Review of the Biologic Literature. <i>Psoriasis Forum</i> , <b>2014</b> , 20a, 96-102		3
164	Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 2202-2211	4.3	42
163	Do we need a patient satisfaction score?. <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 494-5	4	2
162	Biopsy techniques: shave, punch, or excision?. <i>JAMA Dermatology</i> , <b>2014</b> , 150, 12-3	5.1	7
161	From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 70, 178-86	4.5	50
160	Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 666-70	5.1	116
159	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <i>British Journal of Dermatology</i> , <b>2013</b> , 168, 844-54	4	284

158	A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 385-92	4.5	19
157	Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. <i>JAMA Dermatology</i> , <b>2013</b> , 149, 1180-5	5.1	238
156	SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A680.2-A680	2.4	
155	Frequency of Monotherapy versus Combination Therapy in Reported Cases of Infections Occurring in the Setting of Biologic Agents. <i>Psoriasis Forum</i> , <b>2013</b> , 19a, 2-15		1
154	Immune gene expression in primary melanomas to predict lower risk of recurrence and death.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3014-3014	2.2	
153	Interleukin 12/23 inhibitors <b>2013</b> , 319-332.e2		
152	Ingenol mebutate (ingenol 3-angelate, PEP005): focus on its uses in the treatment of nonmelanoma skin cancer. <i>Expert Review of Dermatology</i> , <b>2012</b> , 7, 121-128		7
151	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 731-41	4.5	82
150	Biologic Drugs and Malignancy: A Literature Review Examining the Impact of Concomitant Immunosuppressive Medications. <i>Psoriasis Forum</i> , <b>2012</b> , 18a, 152-163		
149	Ingenol mebutate gel for actinic keratosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1010-9	59.2	379
148	A randomized, double-blind, negatively controlled pilot study to determine whether the use of emollients or calcipotriol alters the sensitivity of the skin to ultraviolet radiation during phototherapy with narrowband ultraviolet B. <i>Yearbook of Dermatology and Dermatologic Surgery</i> , <b>2012</b> , 2012, 204-205		
147	Impact of Baseline Disease Severity Over 26 and 52 Weeks of Treatment with Calcitriol Ointment 3µg/g in Patients with Mild-to-moderate Plaque Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2012</b> , 5, 28-33	1.2	1
146	Iatrogenic effects of biologics for psoriasis. <i>Clinics in Dermatology</i> , <b>2011</b> , 29, 614-21	3	3
145	Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 537-545	4.5	53
144	A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 341-348	4.5	23
143	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 137-74	4.5	343
142	Treatment of Psoriasis in the Setting of Excessive Alcohol Intake: From the Medical Board of the National Psoriasis Foundation. <i>Psoriasis Forum</i> , <b>2011</b> , 17a, 119-130		
141	Biologic Therapy and the Risk of Malignancy in Psoriasis. <i>Psoriasis Forum</i> , <b>2011</b> , 17a, 238-253		3

140	Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients who Relapsed after Adalimumab Discontinuation or Dosage Reduction: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Psoriasis Forum</i> , <b>2011</b> , 17a, 88-96		6
139	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. <i>British Journal of Dermatology</i> , <b>2011</b> , 164, 862-72	4	93
138	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2011</b> , 4, 28-39	1.2	1
137	Cutaneous Carcinogenesis Related to Dermatologic Therapy <b>2011</b> , 349-356		
136	Topical corticosteroids in psoriasis: strategies for improving safety. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2010</b> , 24, 119-24	4.6	42
135	Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 137-46	4	76
134	Tumour necrosis factor- $\alpha$ blockers in the treatment of psoriasis. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 1169-71	4	1
133	Alefacept: where it stands today. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2010</b> , 6, 355-61	5.5	7
132	Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 838-53	4.5	63
131	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 114-135	4.5	267
130	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 571-9	4.5	92
129	Psoriasis and the metabolic syndrome. <i>Dermatologic Therapy</i> , <b>2010</b> , 23, 137-43	2.2	51
128	The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic options. <i>Cutis</i> , <b>2010</b> , 86, suppl 1-11; quiz suppl 12	0.4	9
127	Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 120-4	4.5	53
126	Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 59-62	4.5	21
125	Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 962-71	4.5	73
124	Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 824-37	4.5	233
123	Treatments for psoriasis and the risk of malignancy. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 1001-17	4.5	166

122	Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 60, 643-59	4.5	344
121	Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 61, 451-85	4.5	427
120	Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. <i>Cutis</i> , <b>2009</b> , 83, 205-12	0.4	14
119	Combining systemic retinoids with biologic agents for moderate to severe psoriasis. <i>International Journal of Dermatology</i> , <b>2008</b> , 47, 514-8	1.7	45
118	From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 94-105	4.5	87
117	The effect of weight on the efficacy of biologic therapy in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 443-6	4.5	104
116	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 1031-42	4.5	329
115	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 826-50	4.5	958
114	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 851-64	4.5	349
113	Cutaneous manifestations of cardiovascular diseases. <i>Clinics in Dermatology</i> , <b>2008</b> , 26, 243-54	3	9
112	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). <i>Lancet, The</i> , <b>2008</b> , 371, 1675-84	4.0	1150
111	A Practical Approach to the Use of Infliximab. <i>Psoriasis Forum</i> , <b>2008</b> , 14a, 20-22		
110	Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings. <i>Psoriasis Forum</i> , <b>2008</b> , 14a, 27-34		1
109	Musculoskeletal Symptoms with Long-term Acitretin Therapy for Psoriasis: An Age- and Sex-matched Retrospective Study. <i>Psoriasis Forum</i> , <b>2008</b> , 14a, 4-7		
108	Topical therapy I: corticosteroids and vitamin D analogs <b>2008</b> , 41-55		
107	Topical Immune Response Modifiers: Adjuvants <b>2008</b> , 527-537		
106	Potential complications associated with the use of biologic agents for psoriasis. <i>Dermatologic Clinics</i> , <b>2007</b> , 25, 207-13, vii	4.2	14
105	A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 580-92	59.2	644



104	Effects of Ultraviolet B Exposure on the Expression of Proliferating Cell Nuclear Antigen in Murine Skin. <i>Photochemistry and Photobiology</i> , <b>2007</b> , 80, 587-595	3.6	
103	The Combination of Benzo[a]pyrene and Ultraviolet A Causes an In Vivo Time-related Accumulation of DNA Damage in Mouse Skin. <i>Photochemistry and Photobiology</i> , <b>2007</b> , 77, 413-419	3.6	5
102	Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 57, 957-62	4.5	102
101	Association of patient-reported psoriasis severity with income and employment. <i>Journal of the American Academy of Dermatology</i> , <b>2007</b> , 57, 963-71	4.5	104
100	Therapy for head lice based on life cycle, resistance, and safety considerations. <i>Pediatrics</i> , <b>2007</b> , 119, 965-74	7.4	86
99	Advances in first-line topical therapies: the role of a 2-compound ointment for psoriasis vulgaris. <i>Cutis</i> , <b>2007</b> , 79, 3-4	0.4	
98	Compatibility of topical therapies for psoriasis: challenges and innovations. <i>Cutis</i> , <b>2007</b> , 79, 5-10	0.4	
97	Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. <i>Journal of Drugs in Dermatology</i> , <b>2007</b> , 6, 428-35	2.2	17
96	The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis. <i>Cutis</i> , <b>2007</b> , 80, 29-40	0.4	6
95	Obesity, smoking, and psoriasis. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 208-10	27.4	19
94	The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, 61-3	4.5	44
93	Relapse, rebound, and psoriasis adverse events: an advisory group report. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 54, S171-81	4.5	104
92	A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. <i>Journal of the American Academy of Dermatology</i> , <b>2006</b> , 55, 637-41	4.5	41
91	New roles for systemic retinoids. <i>Journal of Drugs in Dermatology</i> , <b>2006</b> , 5, 406-9	2.2	8
90	The use of systemic immune moderators in dermatology: an update. <i>Dermatologic Clinics</i> , <b>2005</b> , 23, 259-300	4.0	43
89	Use of etanercept in the dermatology setting. A review. <i>American Journal of Clinical Dermatology</i> , <b>2005</b> , 6, 49-59	7.1	11
88	Oral phosphate binders in the treatment of pseudoxanthoma elasticum. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, 610-5	4.5	38
87	An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, 73-5	4.5	42

86	A clinician's paradigm in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, S59-69	4.5	85
85	Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist. <i>Expert Opinion on Biological Therapy</i> , <b>2005</b> , 5, 1505-13	5.4	3
84	No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. <i>Archives of Dermatology</i> , <b>2005</b> , 141, 861-4		41
83	Acanthosis nigricans in a plaque of scleredema on the back of a diabetic patient: a case report. <i>International Journal of Dermatology</i> , <b>2005</b> , 44, 45-7	1.7	4
82	Complications of the smallpox vaccine. <i>International Journal of Dermatology</i> , <b>2005</b> , 44, 289-92	1.7	8
81	The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. <i>Seminars in Arthritis and Rheumatism</i> , <b>2005</b> , 34, 819-36	5.3	171
80	Clinical Efficacy of Efalizumab in Patients with Chronic Plaque Psoriasis: Results from Three Randomized Placebo-Controlled Phase III Trials: Part I. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2005</b> , 9, 303-312	1.6	22
79	Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. <i>Dermatology</i> , <b>2005</b> , 211, 256-63	4.4	18
78	Psoriasis treatment: traditional therapy. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64 Suppl 2, ii83-6	2.4	65
77	Proven efficacy of tacrolimus for facial and intertriginous psoriasis. <i>Archives of Dermatology</i> , <b>2005</b> , 141, 1154		24
76	Vaccination of Patients on Biologic Agents for Psoriasis. <i>Psoriasis Forum</i> , <b>2005</b> , 11a, 7-9		
75	Impaired skin barrier function in dermatologic disease and repair with moisturization. <i>Cutis</i> , <b>2005</b> , 76, 7-12	0.4	34
74	Biologics in combination with nonbiologics: efficacy and safety. <i>Dermatologic Therapy</i> , <b>2004</b> , 17, 432-40	2.2	30
73	Ciclopirox 1% shampoo is a safe and effective treatment for seborrheic dermatitis. <i>International Journal of Dermatology</i> , <b>2004</b> , 43, 1-2	1.7	
72	Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. <i>International Journal of Dermatology</i> , <b>2004</b> , 43 Suppl 1, 17-20	1.7	33
71	Review of therapy of psoriasis: the prebiologic armamentarium. <i>Dermatologic Clinics</i> , <b>2004</b> , 22, 379-88, viii	4.2	2
70	Combination therapy to treat moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, 416-30	4.5	142
69	Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 50, 714-21	4.5	235

68	Innovations in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, S40-1	4.5	5
67	Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, 731-8	4.5	96
66	Tacrolimus ointment is effective for facial and intertriginous psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2004</b> , 51, 723-30	4.5	139
65	An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. <i>Archives of Dermatology</i> , <b>2003</b> , 139, 719-27		271
64	Acitretin suppression of squamous cell carcinoma: case report and literature review. <i>Journal of Dermatological Treatment</i> , <b>2003</b> , 14 Suppl 2, 3-6	2.8	22
63	Case studies in severe psoriasis: A clinical strategy. <i>Journal of Dermatological Treatment</i> , <b>2003</b> , 14 Suppl 2, 26-46	2.8	20
62	Classification of Psoriasis by its Natural History: A New Perspective from Abroad. <i>Psoriasis Forum</i> , <b>2003</b> , 9a, 10-11		1
61	Actinic keratosis: epidemiology and progression to squamous cell carcinoma. <i>British Journal of Dermatology</i> , <b>2003</b> , 149 Suppl 66, 31-3	4	79
60	Topical calcitriol is degraded by ultraviolet light. <i>Journal of Investigative Dermatology</i> , <b>2003</b> , 121, 594-5	4.3	18
59	A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 2004-13	59.2	502
58	Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2003</b> , 14, 7-16	2.8	6
57	Psoriasis. <i>Lancet, The</i> , <b>2003</b> , 361, 1197-204	40	558
56	Combining the new biologic agents with our current psoriasis armamentarium. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 49, S118-24	4.5	49
55	Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. <i>Journal of the American Academy of Dermatology</i> , <b>2003</b> , 48, 760-7	4.5	95
54	A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. <i>International Journal of Dermatology</i> , <b>2002</b> , 41, 269-74	1.7	41
53	Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 47, 553-6	4.5	62
52	Genital lentigines in a 6-year-old boy with a family history of Cowden's disease: clinical and genetic evidence of the linkage between Bannayan-Riley-Ruvacalba syndrome and Cowden's disease. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2001</b> , 5, 228-30	1.6	1
51	Genital Lentigines in a 6-Year-Old Boy with a Family History of Cowden's Disease: Clinical and Genetic Evidence of the Linkage Between Bannayan-Riley-Ruvacalba Syndrome and Cowden's Disease. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2001</b> , 5, 228-230	1.6	11

50	The cost of psoriasis treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2001</b> , 15, 290-291	4.6	
49	Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 44, 77-82	4.5	37
48	Pseudoxanthoma elasticum: significance of limited phenotypic expression in parents of affected offspring. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 44, 534-7	4.5	278
47	Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 45, 544-53	4.5	100
46	Treatment of psoriasis. Part 1. Topical therapy and phototherapy. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 45, 487-98; quiz 499-502	4.5	174
45	Treatment of psoriasis. Part 2. Systemic therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2001</b> , 45, 649-61; quiz 662-4	4.5	158
44	Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. <i>International Journal of Dermatology</i> , <b>2001</b> , 40, 64-6	1.7	33
43	Clinical management of psoriasis: principles and practice. <i>Cutis</i> , <b>2001</b> , 67, 1-15	0.4	3
42	The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. <i>Archives of Dermatology</i> , <b>2001</b> , 137, 280-4		564
41	Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris. <i>Cutis</i> , <b>2001</b> , 67, 261-6	0.4	11
40	Elastin gene deletions in Williams syndrome patients result in altered deposition of elastic fibers in skin and a subclinical dermal phenotype. <i>Pediatric Dermatology</i> , <b>2000</b> , 17, 12-20	1.9	34
39	Cutaneous manifestations of inflammatory bowel disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2000</b> , 14, 349-50	4.6	13
38	A 500-kb region on chromosome 16p13.1 contains the pseudoxanthoma elasticum locus: high-resolution mapping and genomic structure. <i>Journal of Molecular Medicine</i> , <b>2000</b> , 78, 36-46	5.5	51
37	Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. <i>Journal of Experimental Medicine</i> , <b>2000</b> , 193, 121-31	16.6	273
36	Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2000</b> , 42, 428-35	4.5	175
35	Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. <i>Journal of the American Academy of Dermatology</i> , <b>2000</b> , 43, 281-5	4.5	174
34	Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. <i>Journal of the American Academy of Dermatology</i> , <b>2000</b> , 43, S43-6	4.5	26
33	A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. <i>International Journal of Dermatology</i> , <b>1999</b> , 38, 601-6	1.7	23

32	Interactions between tazarotene and ultraviolet light. <i>Journal of the American Academy of Dermatology</i> , <b>1999</b> , 41, 927-30	4.5	39
31	Acitretin in combination with UVB or PUVA. <i>Journal of the American Academy of Dermatology</i> , <b>1999</b> , 41, S22-4	4.5	57
30	Duration of remission of psoriasis therapies. <i>Journal of the American Academy of Dermatology</i> , <b>1999</b> , 41, 51-9	4.5	138
29	CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. <i>Journal of Clinical Investigation</i> , <b>1999</b> , 103, 1243-52	15.9	463
28	Clinically significant therapeutic interactions for the practicing dermatologist. <i>Advances in Dermatology</i> , <b>1999</b> , 14, 1-26; discussion 27		4
27	Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>1998</b> , 39, 590-6	4.5	106
26	Compatibility of calcipotriene with other topical medications. <i>Journal of the American Academy of Dermatology</i> , <b>1998</b> , 38, 1010-1	4.5	76
25	Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. <i>Journal of the American Academy of Dermatology</i> , <b>1998</b> , 39, 447-50	4.5	92
24	Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>1998</b> , 39, 464-75	4.5	163
23	Methotrexate in psoriasis: consensus conference. <i>Journal of the American Academy of Dermatology</i> , <b>1998</b> , 38, 478-85	4.5	288
22	Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>1998</b> , 38, 705-11	4.5	72
21	New horizons in the management of psoriasis: introduction. <i>Cutis</i> , <b>1998</b> , 61, 7	0.4	
20	Clinical efficacy and safety of tazarotene: optimizing clinical results. <i>Cutis</i> , <b>1998</b> , 61, 27-9	0.4	3
19	Tacalcitol : A Viewpoint by J. Baral and M. Lebwohl. <i>Drugs</i> , <b>1997</b> , 54, 272	12.1	
18	Interactions between calcipotriene and ultraviolet light. <i>Journal of the American Academy of Dermatology</i> , <b>1997</b> , 37, 93-5	4.5	73
17	Topical calcipotriene in combination with UVB phototherapy for psoriasis. <i>International Journal of Dermatology</i> , <b>1997</b> , 36, 302-3	1.7	42
16	Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient. <i>International Journal of Dermatology</i> , <b>1997</b> , 36, 205-7	1.7	18
15	Topical application of calcipotriene and corticosteroids: combination regimens. <i>Journal of the American Academy of Dermatology</i> , <b>1997</b> , 37, S55-8	4.5	16

14	A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>1996</b> , 35, 268-9	4.5	123
13	Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. <i>Cutis</i> , <b>1996</b> , 57, 62-8	0.4	12
12	Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. <i>Journal of the American Academy of Dermatology</i> , <b>1995</b> , 32, 469-71	4.5	55
11	Topical therapy for psoriasis. <i>International Journal of Dermatology</i> , <b>1995</b> , 34, 673-84	1.7	23
10	Classification of pseudoxanthoma elasticum: report of a consensus conference. <i>Journal of the American Academy of Dermatology</i> , <b>1994</b> , 30, 103-7	4.5	140
9	Brief report: occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 1237-9	59.2	85
8	Abnormalities of connective tissue components in lesional and non-lesional tissue of patients with pseudoxanthoma elasticum. <i>Archives of Dermatological Research</i> , <b>1993</b> , 285, 121-6	3.3	44
7	Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy. <i>International Journal of Dermatology</i> , <b>1993</b> , 32, 830-1	1.7	13
6	Collagen alterations in chronically sun-damaged human skin. <i>Photochemistry and Photobiology</i> , <b>1993</b> , 58, 841-4	3.6	107
5	Differential diagnosis of pigmented lesions of the skin. <i>Mount Sinai Journal of Medicine</i> , <b>1992</b> , 59, 194-7		1
4	Interferon and condylomata acuminata. <i>International Journal of Dermatology</i> , <b>1990</b> , 29, 699-705	1.7	9
3	Pseudoxanthoma elasticum and mitral-valve prolapse. <i>New England Journal of Medicine</i> , <b>1982</b> , 307, 228-30	39.2	118
2	The disease burden of generalized pustular psoriasis: Real-world evidence from CorEvitas Psoriasis Registry. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 247553032210798	1.1	2
1	Improving Access to Care for Patients with Psoriasis and Psoriatic Arthritis: The Impact of the Temporary Reciprocity to Ensure Access to Treatment Act and Remote Care Policy Reform. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 247553032110672	1.1	